Condition: Solid Tumor Malignancies · Brain Metastases From Solid Tumors · Sponsor: A2A Pharmaceuticals Inc.
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
This description comes directly from the study's public registry record.
Robbin Frnka, Chief ClinOps Officer · 2142055746 · rfrnka@coiledtx.com
Always discuss trial participation with your own doctor first.
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Oklahoma Univeristy | Oklahoma City, Oklahoma, United States | Recruiting |
| Hollings Cancer Center - MUSC | Charleston, South Carolina, United States | Recruiting |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Recruiting |
| The University of Texas M.D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Next Oncology -Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06136884